1. Market Research
  2. > Healthcare
  3. > Medical Supply Market Trends
  4. > Leg Ulcers – Pipeline Review, H1 2013

Leg Ulcers – Pipeline Review, H1 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 70 pages

Leg Ulcers – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Leg Ulcers - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Leg Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leg Ulcers. Leg Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Leg Ulcers.
- A review of the Leg Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Leg Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Leg Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Leg Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Leg Ulcers - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Leg Ulcers Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Leg Ulcers 8
Leg Ulcers Therapeutics under Development by Companies 10
Leg Ulcers Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
Leg Ulcers Therapeutics - Products under Development by Companies 16
Leg Ulcers Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Leg Ulcers Therapeutics Development 18
RegeneRx Biopharmaceuticals, Inc. 18
CytoTools AG 19
Healthpoint, Ltd. 20
Glycotex, Inc. 21
FirstString Research, Inc. 22
CoDa Therapeutics, Inc. 23
Adocia 24
Leg Ulcers - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
RGN-137 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
ICX-PRO - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
GLYC-101 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
DermaPro CI-05 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Biochaperone PDGF-BB - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
HP802-247 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
HO/03/03 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Nexagon - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
LyphoDerm - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
adalimumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
PV-702 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
repifermin - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
LL-37 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
PPA-904 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Granexin - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Drug For Venous Statis Ulcer - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
Leg Ulcers Therapeutics - Drug Profile Updates 53
Leg Ulcers Therapeutics - Discontinued Products 59
Leg Ulcers Therapeutics - Dormant Products 60
Leg Ulcers - Product Development Milestones 62
Featured News and Press Releases 62
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 62
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds 62
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 63
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 64
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 65
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 65
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 66
Dec 20, 2004: RegeneRx Files With FDA For Second Phase II Clinical Trial 66
Jun 23, 2004: Sigma-Tau Conducts Phase II Clinical Trial In Europe With Tß4 For Venous Stasis Ulcers 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70



List of Tables

Number of Products Under Development for Leg Ulcers, H1 2013 8
Products under Development for Leg Ulcers - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
RegeneRx Biopharmaceuticals, Inc., H1 2013 18
CytoTools AG, H1 2013 19
Healthpoint, Ltd., H1 2013 20
Glycotex, Inc., H1 2013 21
FirstString Research, Inc., H1 2013 22
CoDa Therapeutics, Inc., H1 2013 23
Adocia, H1 2013 24
Assessment by Monotherapy Products, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 29
Leg Ulcers Therapeutics - Drug Profile Updates 53
Leg Ulcers Therapeutics - Discontinued Products 59
Leg Ulcers Therapeutics - Dormant Products 60
Leg Ulcers Therapeutics - Dormant Products (Contd..1) 61



List of Figures

Number of Products under Development for Leg Ulcers, H1 2013 8
Products under Development for Leg Ulcers - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Pre-Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 25
Assessment by Route of Administration, H1 2013 26
Assessment by Stage and Route of Administration, H1 2013 27
Assessment by Molecule Type, H1 2013 28
Assessment by Stage and Molecule Type, H1 2013 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
LifeBond Ltd. - Product Pipeline Analysis, 2016 Update

LifeBond Ltd. - Product Pipeline Analysis, 2016 Update

  • $ 750
  • Company report
  • August 2016
  • by Global Data

Summary LifeBond Ltd. (LifeBond) is a medical device company that develops medical devices for bio-surgery and tissue repair. The company’s products comprise lifeseal surgical sealant and lifemesh self-fixating ...

Wound Management Technologies, Inc. (WNDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Wound Management Technologies, Inc. (WNDM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • September 2016
  • by Global Data

Summary Wound Management Technologies, Inc. (WMT) is a medical device company. It develops and markets advanced wound care products. The company offers its patented product CellerateRX in powder (collagen) ...

Derma Sciences, Inc. (DSCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Derma Sciences, Inc. (DSCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2016
  • by Global Data

Summary Derma Sciences, Inc. (Derma Sciences) is a medical. It focuses on advanced wound care and traditional wound care. Its advanced wound care product portfolio includes dermagran, silverseal, alginate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.